Trends in Newly Filled GLP-1 Receptor Agonist Prescriptions for US Patients With Versus Without Comorbid Alcohol Use Disorder, 2016–2024
From 2016 to 2024, the rate of newly filled GLP-1RA prescriptions increased among individuals with T2DM and/or obesity and comorbid AUD. Individuals with comorbid AUD were more likely to be male and to have clinical characteristics linked to greater AUD severity. Additional clinical studies on the efficacy and safety of GLP-1RAs for AUD are needed to guide their appropriate use.
Authors
- Samuel T. Savitz (ORCID: https://orcid.org/0000-0003-3190-7740)
- Kasia J. Lipska (ORCID: https://orcid.org/0000-0002-0348-742X)
- Joseph S. Ross (ORCID: https://orcid.org/0000-0002-9218-3320)
- Joshua D. Wallach (ORCID: https://orcid.org/0000-0002-2816-6905)
- Stephanie S. O’Malley (ORCID: https://orcid.org/0000-0002-1976-2369)
- Molly M. Jeffery (ORCID: https://orcid.org/0000-0003-3854-6810)
Institutions
- Emory University (US)
- School of the Art Institute of Chicago (US)
- Yale University (US)
Publication Details
- Journal
- Journal of Addiction Medicine
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1097/adm.0000000000001575
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59